Regeneron Pharmaceuticals (NASDAQ:REGN) outlined its C5 complement development strategy in an investor roundtable focused on cemdisiran, an siRNA targeting C5, and pozelimab, a C5-targeting antibody ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare immune disease that causes your body to break down red blood cells when it should not. This disorder happens when there is a problem with certain ...
Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced the first patient has been dosed in multiple Phase II studies of ...
These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance. In ...
In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment. Carlos M. De Castro, MD: I’d love to say we need more studies, studying ...
Ilene Weitz, MD, details a few abstracts on paroxysmal nocturnal hemoglobinuria (PNH) treatments that will be presented at ASH 2024, particularly data on danicopan as an add-on to ravulizumab or ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease that can cause fatigue due to anemia. PNH is closely associated with fatigue due to a loss of red blood cells, leading to anemia. This ...
The FDA approved the complement C5 inhibitor crovalimab (Piasky) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening blood disease. Indicated for PNH in adults and ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...
Carlos M. De Castro, MD, highlights the phase III Apply-PNH study presented at ASH 2022. Carlos M. De Castro, MD: In PNH [paroxysmal nocturnal hemoglobinuria], the needs are 2-fold. Over the past 20 ...
Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results